Argenx Targets 50,000 Patients by 2030 as CEO Highlights $1B Vyvgart Sales and 2026 Catalysts
Argenx CEO Karen Massey reaffirmed Vision 2030 to treat 50,000 patients, secure 10 indications and advance five molecules, citing $1 billion in VYVGART sales. She flagged 2026 readouts in myositis, MMN and Sjögren’s, data updates for ARGX-213 and ARGX-124, and phase 2 progress in IgA nephropathy.
1. Vision 2030 Objectives
Karen Massey reiterated Arg en x’s commitment to its Vision 2030 roadmap: treating 50,000 patients, securing 10 labeled indications and advancing five molecules into late-stage development, while maintaining leadership in the FcRn space.
2. VYVGART Performance and MG Franchise
VYVGART achieved $1 billion in annual sales and captures six out of 10 new myasthenia gravis biologic starts, with a May PDUFA date for seronegative MG and ongoing ocular MG data showcasing meaningful symptom and quality-of-life benefits.
3. Pipeline Catalysts for 2026
Multiple catalysts are on deck, including clinical readouts in myositis, multifocal motor neuropathy, Sjögren’s syndrome and chronic inflammatory demyelinating polyneuropathy, alongside strategic studies of empasiprubart (MMN and CIDP) and an oral peptide collaboration to expand dosing options.
4. Next-Generation Programs and IgA Sweeper
Argenx plans to share human data for ARGX-213 and ARGX-124 later this year and is advancing an IgA-sweeper into a phase 2 IgA nephropathy trial, with potential expansion into IgA vasculitis driven by rapid IgA reduction and 28-day dosing prospects.